Pyroptosis, apoptosis, and necroptosis are mainly programmed cell death (PCD) pathways for host defense and homeostasis. PANoptosis is a newly distinct inflammatory PCD pathway that is uniquely regulated by multifaceted PANoptosome complexes and highlights significant crosstalk and coordination among pyroptosis (P), apoptosis (A), and/or necroptosis(N). Although some studies have focused on the possible role of PANpoptosis in diseases, the pathogenesis of PANoptosis is complex and underestimated. Furthermore, the progress of PANoptosis and related agonists or inhibitors in disorders has not yet been thoroughly discussed. In this perspective, we provide perspectives on PANoptosome and PANoptosis in the context of diverse pathological conditions and human diseases. The treatment targeting on PANoptosis is also summarized. In conclusion, PANoptosis is involved in plenty of disorders including but not limited to microbial infections, cancers, acute lung injury/acute respiratory distress syndrome (ALI/ARDS), ischemia-reperfusion, and organic failure. PANoptosis seems to be a double-edged sword in diverse conditions, as PANoptosis induces a negative impact on treatment and prognosis in disorders like COVID-19 and ALI/ARDS, while PANoptosis provides host protection from HSV1 or Francisella novicida infection, and kills cancer cells and suppresses tumor growth in colorectal cancer, adrenocortical carcinoma, and other cancers. Compounds and endogenous molecules focused on PANoptosis are promising therapeutic strategies, which can act on PANoptosomes-associated members to regulate PANoptosis. More researches on PANoptosis are needed to better understand the pathology of human conditions and develop better treatment.
16 September 2019 in Journal of Cosmetic Dermatology
Macular amyloidosis and lichenoid amyloidosis are the types of primary cutaneous amyloidosis, characterized by deposition of amyloid in the upper dermis, without other cutaneous or systemic disorders. Clinically, the association of macular amyloidosis and lichenoid amyloidosis is termed biphasic amyloidosis. Patients with facial involvement are rare but they are likely to experience low self‐esteem. Although there are various therapeutic modalities, none is completely satisfactory. Previous studies described macular amyloidosis and lichenoid amyloidosis were associated with apoptosis of keratinocytes. As salicylic acid is an excellent keratinizing agent, we applied salicylic acid in a patient who was diagnosed as biphasic amyloidosis with facial involvement. To our knowledge, this is the first report that biphasic amyloidosis with facial involvement had obvious improvement after treatment of 30% salicylic acid.